Its key distinction is high selectivity it does not significantly affect cortisol, prolactin, or appetite
Menezo YJ, Hazout A, Panteix G, Robert F, Rollet J, Cohen-Bacrie P, Chapuis F, Clement P, Benkhalifa M
If you are pregnant or planning to become pregnant, discuss the potential risks and benefits of GLP-1 analogues with your healthcare provider
long-acting GLP-1RAs on AMD, long-acting agents are known to be more effective in terms of glycemic control and body weight, and it has been suggested that weight-loss mediated pathways may drive the ocular benefits associated with GLP-1RA use. However, they pointed out that this study cohort was matched for hemoglobin A1c and BMI, which decreases the likelihood that the more pronounced benefit associated with long-term agents is due to these factors alone. Moreover, in obese and non-obese individuals, GLP-1 agonist therapy exhibited comparable reduced risks of dry (21% vs